As an alpha-lipoic acid analogue, CPI-613 has been used to halt cancer cell multiplication and survival by selectively targeting PDH and α-KGDH, which are critical to the mitochondrial TCA cycle [3, 7]. This evidence concerns the gene PDP1 and cancer.